| Anetumab ravtansine: a novel mesothelin-targeting antibody–drug conjugate cures tumors with heterogeneous target expression favored by bystander effect S Golfier, C Kopitz, A Kahnert, I Heisler, CA Schatz, B Stelte-Ludwig, ... Molecular cancer therapeutics 13 (6), 1537-1548, 2014 | 223 | 2014 |
| The Crystal Structures of Zea mays and Arabidopsis 4-Hydroxyphenylpyruvate Dioxygenase IM Fritze, L Linden, J Freigang, G Auerbach, R Huber, S Steinbacher Plant Physiology 134 (4), 1388-1400, 2004 | 144 | 2004 |
| With or without sugar?(A) glycosylation of therapeutic antibodies D Hristodorov, R Fischer, L Linden Molecular biotechnology 54, 1056-1068, 2013 | 82 | 2013 |
| Generation and comparative characterization of glycosylated and aglycosylated human IgG1 antibodies D Hristodorov, R Fischer, H Joerissen, B Müller-Tiemann, H Apeler, ... Molecular biotechnology 53, 326-335, 2013 | 78 | 2013 |
| Synergistic effect of a mesothelin-targeted 227Th conjugate in combination with DNA damage response inhibitors in ovarian cancer xenograft models K Wickstroem, UB Hagemann, V Cruciani, AM Wengner, A Kristian, ... Journal of Nuclear Medicine 60 (9), 1293-1300, 2019 | 46 | 2019 |
| Preclinical antitumor efficacy of BAY 1129980—a novel auristatin-based anti-C4. 4A (LYPD3) antibody–drug conjugate for the treatment of non–small cell lung cancer J Willuda, L Linden, HG Lerchen, C Kopitz, B Stelte-Ludwig, C Pena, ... Molecular cancer therapeutics 16 (5), 893-904, 2017 | 44 | 2017 |
| Salt-induced aggregation of a monoclonal human immunoglobulin G1 J Rubin, L Linden, WM Coco, AS Bommarius, SH Behrens Journal of Pharmaceutical Sciences 102 (2), 377-386, 2013 | 36 | 2013 |
| New binder-drug conjugates (adcs) and use thereof HG Lerchen, L Linden, S El Sheikh, J Willuda, CC Kopitz, J Schuhmacher, ... US Patent App. 15/052,655, 2016 | 34* | 2016 |
| Calcium modulates rapid protein phosphorylation/dephosphorylation in isolated eyespot apparatuses of the green alga Spermatozopsis similis L Linden, G Kreimer Planta 197 (2), 343-351, 1995 | 34 | 1995 |
| Synergistic effect of a HER2 targeted thorium-227 conjugate in combination with olaparib in a BRCA2 deficient xenograft model K Wickstroem, J Karlsson, C Ellingsen, V Cruciani, A Kristian, ... Pharmaceuticals 12 (4), 155, 2019 | 32 | 2019 |
| Targeted inhibition of activated protein C by a non-active-site inhibitory antibody to treat hemophilia XY Zhao, A Wilmen, D Wang, X Wang, M Bauzon, JY Kim, L Linden, L Li, ... Nature Communications 11 (1), 2992, 2020 | 25 | 2020 |
| Relaxin fusion polypeptides and uses thereof A Wilmen, U Haupts, C Freiberg, M Trautwein, L Linden, K Leineweber, ... US Patent 9,382,305, 2016 | 24 | 2016 |
| REFOLDED MEMBRANE PROTEIN IN MONODISPERSE FORM L LINDEN, S PRYTULLA, T OSTERMANN, M BAEHNER, T ROOS, ... WO Patent 2,005,058,942, 2005 | 24 | 2005 |
| Biophysical and sequence-based methods for identifying monovalent and bivalent antibodies with high colloidal stability ME Alam, SB Geng, C Bender, SD Ludwig, L Linden, R Hoet, PM Tessier Molecular Pharmaceutics 15 (1), 150-163, 2018 | 23 | 2018 |
| G proteins and Ca2+-modulated protein kinases of a plasma membrane-enriched fraction and isolated eyespot apparatuses of Spermatozopsis similis (Chlorophyceae) U Schlicher, L Linden, M Calenberg, G Kreimer European Journal of Phycology 30 (4), 319-330, 1995 | 23 | 1995 |
| Preclinical combination studies of an FGFR2 targeted thorium-227 conjugate and the ATR inhibitor BAY 1895344 K Wickstroem, UB Hagemann, A Kristian, C Ellingsen, A Sommer, ... International Journal of Radiation Oncology* Biology* Physics 105 (2), 410-422, 2019 | 21 | 2019 |
| Gauging colloidal and thermal stability in human IgG1–sugar solutions through diffusivity measurements J Rubin, A Sharma, L Linden, AS Bommarius, SH Behrens The Journal of Physical Chemistry B 118 (11), 2803-2809, 2014 | 21 | 2014 |
| NOVEL BINDER-DRUG CONJUGATES (ADCS) AND THEIR USE HG LERCHEN, L LINDEN, S EL SHEIKH, J WILLUDA, C KOPITZ, ... WO Patent 2,012,143,497, 2012 | 18* | 2012 |
| Neutralizing prolactin receptor antibody Mat3 and its therapeutic use C Freiberg, C Otto, L Linden, A Harrenga, M Trautwein, S Greven, ... US Patent 9,353,186, 2016 | 15 | 2016 |
| Evaluation of human pancreatic RNase as effector molecule in a therapeutic antibody platform T Schirrmann, A Frenzel, L Linden, B Stelte-Ludwig, J Willuda, ... MAbs 6 (2), 367-380, 2014 | 12 | 2014 |
